Myovant Sciences Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Total Funding:$217.5M
Industry:Biotech
Founded:2016
Lead Investor(s):J.P. Morgan Securities LLC
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Myovant Sciences's estimated annual revenue is currently $15.7M per year.
  • Myovant Sciences received $86.2M in venture funding in July 2018.
  • Myovant Sciences's estimated revenue per employee is $70,518
  • Myovant Sciences's total funding is $217.5M.

Employee Data

  • Myovant Sciences has 222 Employees.
  • Myovant Sciences grew their employee count by 24% last year.
  • Myovant Sciences currently has 38 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.7M4310%N/A
Mission Bio
$11.5M7445%N/A
Geron Corporati...
N/A197N/AN/A
Rigel Pharmaceu...
$45M2904%N/A
Althea Technolo...
$21.4M138N/AN/A
INOVA Diagnosti...
$37.5M242N/AN/A
ProTrials Resea...
$28.2M1823%N/A
Trace Genomics
$6.4M4137%N/A
Advanced Cell D...
$27.6M1788%N/A
The J. Craig Ve...
$33.3M215N/AN/A
Missing a competitor? Contribute!?
Submit

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant's lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women's health and endocrine-related disorders. For more information, please visit the company's website at myovant.com.

keywords:N/A

222

Number of Employees

$15.7M

Revenue (est)

38

Current Jobs

24%

Employee Growth %

$217.5M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Lynn SeelyPresident & CEOEmail Available
Jack ThornquestBusiness Development Manager
David AlonzoAssociate Director
Griffin BarbulaStellvertretender Director, Analytical Development and Quality Control
Emmanuel AngClinical Trial Manager
Michael BrandlPrincipal Scientist
David Hansenior manager, contract manufacturing
Jennifer HodgeVP, Development Operations
Tera MathewsDirector, Clinical Operations Systems, Solutions & Process
Julia ItskevitchPrincipal Statistical Programmer

Myovant Sciences News

07-Sep-19 - $3B package deal to push Peninsula company into arms of Japanese drugmaker

Former hedge fund partner Vivek Ramaswamy's collection of "vants" — including Brisbane-based, women's health-focused Myovant Sciences ...

24-Aug-19 - CORRECTION: Myovant Sciences to Participate in Upcoming ...

Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for ...

12-Sep-19 - Is Something Really Weird Happening In Myovant Sciences Ltd. (MYOV), Office Depot (ODP)

The recent performance of Myovant Sciences Ltd. (NYSE:MYOV) stock in the market spoke loud and clear to investors as MYOV saw more than ...

Myovant Sciences Funding

DateAmountRoundLead InvestorsReference
2017-10-17$140.0MUndisclosedNovaQuest Capital ManagementArticle
2018-07-12$86.2MUndisclosedJ.P. Morgan Securities LLCArticle

Myovant Sciences Executive Hires

DateNameTitleReference
2017-07-21Matthew LangGeneral Counsel/Corporate SecretaryArticle
2018-11-08Kim SablichChief Commercial OfficerArticle